Provided is a protein derived from Tumebacillus sp. NITE BP-02779 and having peptidoglycan-degrading activity. Provided is a protein comprising the amino acid sequence at positions 1 to 164 of SEQ ID NO: 2 or the amino acid sequence at positions 1 to 493 of SEQ ID NO: 4, or the amino acid sequences with a substitution, deletion, insertion, or addition of 1 to 10 amino acid residues, or an amino acid sequence having 90% or more identity to the amino acid sequences, and having peptidoglycan-degrading activity.

Provided is a protein derived from Tumebacillus sp. NITE BP-02779 and having peptidoglycan-degrading activity. Provided is a protein comprising the amino acid sequence at positions 1 to 164 of SEQ ID NO: 2 or the amino acid sequence at positions 1 to 493 of SEQ ID NO: 4, or the amino acid sequences with a substitution, deletion, insertion, or addition of 1 to 10 amino acid residues, or an amino acid sequence having 90% or more identity to the amino acid sequences, and having peptidoglycan-degrading activity.

The present disclosure provides expression vectors and bacterial sequence-free vectors, such as ministring DNA (msDNA), for producing virus-like particles (VLPs) as well as compositions and methods thereof. In some aspects, the methods include treating viral infections in subjects with the vectors, compositions, and VLPs.

This invention concerns a method for preparing a bacterial supernatant comprising culturing a cell of Pseudomonas environmental strain PF-11; and recovering the supernatant. This invention also concerns a method for reducing the amount of a biofilm on a surface, reducing adhesion of at least one organism to a surface, or reducing microfouling or macrofouling on a surface comprising contacting the surface with a supernatant, supernatant fraction, modified supernatant or modified supernatant fraction of Pseudomonas strain PF-11; or a composition comprising a supernatant, supernatant fraction, modified supernatant or modified supernatant fraction of Pseudomonas strain PF-11, and one or more acceptable carriers. This invention also concerns a method for killing or reducing the growth of a fungus or bacterial cell, or killing or inhibiting the development of an insect or marine copepod, comprising contacting the fungus, bacteria, insect or marine copepod with a supernatant, supernatant fraction, modified supernatant or modified supernatant fraction of a Pseudomonas strain PF-11 culture; or a composition comprising a supernatant, supernatant fraction, modified supernatant or modified supernatant fraction of a Pseudomonas strain PF-11 culture, and one or more acceptable carriers. This invention also concerns a substantially pure culture of Pseudomonas strain PF-11. This invention also concerns a culture that is enriched in Pseudomonas strain PF-11. This invention also provides a method of identifying whether a bacteria is capable of producing one or more extracellular proteases capable of digesting a high molecular weight substrate.

Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.

An automatic dishwashing cleaning composition having a new protease.

An automatic dishwashing cleaning composition having a new protease.

Human ACE2 variants are provided including methods of use thereof. The ACE2 receptor variants may be used for diagnosis and treatment of COVID-19.

The present invention relates to granzyme B variants with increased protease activities and/or increased resistance against inhibitors; polynucleotides encoding the granzyme B variants; cells expressing the granzyme B variants; pharmaceutical compositions containing cells expressing the granzyme B variants; and pharmaceutical compositions containing the granzyme B variants. In some embodiments, the pharmaceutical compositions may be used in combination with cells expressing chimera receptors and/or antigen-binding molecules.

Provided is a method which can produce a target protein while stably maintaining a vector without any special genetic manipulation of host cells and without use of a drug resistance gene or the like. A method for producing a target protein including culturing cells transformed with a vector, the vector containing a gene of the target protein and not containing an antibiotic resistance gene, a recombinase recognition sequence, or a gene essential for cell survival.